
Shannon Leigh Risacher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3978057/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	27.8	772
2	The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging and Behavior, 2014, 8, 153-182.	2.1	696
3	Identification of common variants associated with human hippocampal and intracranial volumes. Nature Genetics, 2012, 44, 552-561.	21.4	594
4	Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort. Current Alzheimer Research, 2009, 6, 347-361.	1.4	484
5	The genetic architecture of the human cerebral cortex. Science, 2020, 367, .	12.6	450
6	Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome. Alzheimer's and Dementia, 2019, 15, 76-92.	0.8	396
7	Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimer's and Dementia, 2010, 6, 265-273.	0.8	378
8	Metabolic network failures in Alzheimer's disease: A biochemical roadÂmap. Alzheimer's and Dementia, 2017, 13, 965-984.	0.8	362
9	Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. NeuroImage, 2010, 53, 1051-1063.	4.2	340
10	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. Journal of Alzheimer's Disease, 2015, 48, S63-S86.	2.6	317
11	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	12.8	250
12	Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimer's and Dementia, 2015, 11, 792-814.	0.8	241
13	Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurology, 2016, 73, 721.	9.0	235
14	Subjective cognitive decline and rates of incident Alzheimer's disease and non–Alzheimer's disease dementia. Alzheimer's and Dementia, 2019, 15, 465-476.	0.8	232
15	Longitudinal MRI atrophy biomarkers: Relationship to conversion in the ADNI cohort. Neurobiology of Aging, 2010, 31, 1401-1418.	3.1	230
16	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	14.8	213
17	Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimer's and Dementia, 2019, 15, 232-244.	0.8	198
18	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	21.4	192

#	Article	IF	CITATIONS
19	Network approaches to systems biology analysis of complex disease: integrative methods for multi-omics data. Briefings in Bioinformatics, 2018, 19, 1370-1381.	6.5	185
20	APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Molecular Psychiatry, 2014, 19, 351-357.	7.9	181
21	Genetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers. Brain Imaging and Behavior, 2014, 8, 183-207.	2.1	161
22	<i>APOE</i> effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimer's and Dementia, 2015, 11, 1417-1429.	0.8	157
23	Identifying quantitative trait loci via group-sparse multitask regression and feature selection: an imaging genetics study of the ADNI cohort. Bioinformatics, 2012, 28, 229-237.	4.1	149
24	Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. JAMA Network Open, 2019, 2, e197978.	5.9	142
25	Altered Default Mode Network Connectivity in Older Adults with Cognitive Complaints and Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2013, 35, 751-760.	2.6	135
26	The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Frontiers in Aging Neuroscience, 2013, 5, 11.	3.4	126
27	Visual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints. Neurobiology of Aging, 2013, 34, 1133-1144.	3.1	123
28	Neuropathological correlates and genetic architecture of microglial activation in elderly human brain. Nature Communications, 2019, 10, 409.	12.8	121
29	APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 127-134.	1.9	118
30	GWAS of longitudinal amyloid accumulation on ¹⁸ F-florbetapir PET in Alzheimer's disease implicates microglial activation gene <i>IL1RAP</i> . Brain, 2015, 138, 3076-3088.	7.6	117
31	Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline. Neurology, 2017, 89, 2176-2186.	1.1	115
32	Identifying disease sensitive and quantitative trait-relevant biomarkers from multidimensional heterogeneous imaging genetics data via sparse multimodal multitask learning. Bioinformatics, 2012, 28, i127-i136.	4.1	114
33	A large scale multivariate parallel ICA method reveals novel imaging–genetic relationships for Alzheimer's disease in the ADNI cohort. NeuroImage, 2012, 60, 1608-1621.	4.2	111
34	Neuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection. Annual Review of Clinical Psychology, 2013, 9, 621-648.	12.3	110
35	Neuroimaging Biomarkers of Neurodegenerative Diseases and Dementia. Seminars in Neurology, 2013, 33, 386-416.	1.4	110
36	Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis. JAMA Neurology, 2018, 75, 328.	9.0	101

#	Article	IF	CITATIONS
37	Multi-modal neuroimaging feature selection with consistent metric constraint for diagnosis of Alzheimer's disease. Medical Image Analysis, 2020, 60, 101625.	11.6	99
38	Structured sparse canonical correlation analysis for brain imaging genetics: an improved GraphNet method. Bioinformatics, 2016, 32, 1544-1551.	4.1	96
39	The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests. Journal of Alzheimer's Disease, 2016, 51, 1145-1155.	2.6	93
40	Selfâ€rated and informantâ€rated everyday function in comparison to objective markers of Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1080-1089.	0.8	85
41	Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Molecular Psychiatry, 2013, 18, 781-787.	7.9	81
42	Type 2 diabetes mellitus is associated with brain atrophy and hypometabolism in the ADNI cohort. Neurology, 2016, 87, 595-600.	1.1	81
43	Plasma amyloid beta levels are associated with cerebral amyloid and tau deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 510-519.	2.4	77
44	Comparison of Manual and Automated Determination of Hippocampal Volumes in MCI and Early AD. Brain Imaging and Behavior, 2010, 4, 86-95.	2.1	74
45	Sparse multi-task regression and feature selection to identify brain imaging predictors for memory performance. , 2011, , 557-562.		72
46	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging, 2017, 60, 92-103.	3.1	70
47	Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease. Brain Imaging and Behavior, 2012, 6, 551-567.	2.1	66
48	Serum triglycerides in Alzheimer disease. Neurology, 2020, 94, e2088-e2098.	1.1	63
49	From phenotype to genotype: an association study of longitudinal phenotypic markers to Alzheimer's disease relevant SNPs. Bioinformatics, 2012, 28, i619-i625.	4.1	62
50	Genetic correlations and genome-wide associations of cortical structure in general population samples of 22,824 adults. Nature Communications, 2020, 11, 4796.	12.8	61
51	Multiple loci influencing hippocampal degeneration identified by genome scan. Annals of Neurology, 2012, 72, 65-75.	5.3	59
52	Traumatic brain injury and age at onset of cognitive impairment in older adults. Journal of Neurology, 2016, 263, 1280-1285.	3.6	59
53	Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging and Behavior, 2012, 6, 634-648.	2.1	58
54	Transcriptome-guided amyloid imaging genetic analysis via a novel structured sparse learning algorithm. Bioinformatics, 2014, 30, i564-i571.	4.1	57

Shannon Leigh Risacher

#	Article	IF	CITATIONS
55	Bundle analytics, a computational framework for investigating the shapes and profiles of brain pathways across populations. Scientific Reports, 2020, 10, 17149.	3.3	57
56	Identifying AD-Sensitive and Cognition-Relevant Imaging Biomarkers via Joint Classification and Regression. Lecture Notes in Computer Science, 2011, 14, 115-123.	1.3	57
57	Influence of <i>TSPO</i> Genotype on ¹¹ C-PBR28 Standardized Uptake Values. Journal of Nuclear Medicine, 2013, 54, 1320-1322.	5.0	56
58	Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 58, 1245-1254.	2.6	54
59	Detecting genetic associations with brain imaging phenotypes in Alzheimer's disease via a novel structured SCCA approach. Medical Image Analysis, 2020, 61, 101656.	11.6	53
60	Identifying Neuroimaging and Proteomic Biomarkers for MCI and AD via the Elastic Net. Lecture Notes in Computer Science, 2011, 7012, 27-34.	1.3	53
61	Cognitive complaints in older adults at risk for Alzheimer's disease are associated with altered restingâ€state networks. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 40-49.	2.4	52
62	Genomic Copy Number Analysis in Alzheimer's Disease and Mild Cognitive Impairment: An ADNI Study. International Journal of Alzheimer's Disease, 2011, 2011, 1-10.	2.0	51
63	Resting state network modularity along the prodromal late onset Alzheimer's disease continuum. Neurolmage: Clinical, 2019, 22, 101687.	2.7	51
64	White matter alterations in earlyâ€stage Alzheimer's disease: A tractâ€specific study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 576-587.	2.4	50
65	Influence of Genetic Variation on Plasma Protein Levels in Older Adults Using a Multi-Analyte Panel. PLoS ONE, 2013, 8, e70269.	2.5	50
66	Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. Scientific Data, 2017, 4, 170140.	5.3	49
67	Protective variant for hippocampal atrophy identified by whole exome sequencing. Annals of Neurology, 2015, 77, 547-552.	5.3	48
68	Relationship between baseline brain metabolism measured using [18F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging and Behavior, 2012, 6, 568-583.	2.1	47
69	Amyloid pathway-based candidate gene analysis of [11C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging and Behavior, 2012, 6, 1-15.	2.1	47
70	Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Molecular Psychiatry, 2021, 26, 309-321.	7.9	47
71	Mining Outcome-relevant Brain Imaging Genetic Associations via Three-way Sparse Canonical Correlation Analysis in Alzheimer's Disease. Scientific Reports, 2017, 7, 44272.	3.3	44
72	Olfactory identification in subjective cognitive decline and mild cognitive impairment: Association with tau but not amyloid positron emission tomography. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 57-66.	2.4	44

#	Article	IF	CITATIONS
73	Association of cancer history with Alzheimer's disease onset and structural brain changes. Frontiers in Physiology, 2014, 5, 423.	2.8	43
74	Association of plasma and cortical amyloid beta is modulated by <i>APOE</i> Îμ4 status. Alzheimer's and Dementia, 2014, 10, e9-e18.	0.8	43
75	Cortical surface biomarkers for predicting cognitive outcomes using group l2,1 norm. Neurobiology of Aging, 2015, 36, S185-S193.	3.1	43
76	Identification of associations between genotypes and longitudinal phenotypes via temporally-constrained group sparse canonical correlation analysis. Bioinformatics, 2017, 33, i341-i349.	4.1	42
77	The Structural and Functional Connectome and Prediction of Risk for Cognitive Impairment in Older Adults. Current Behavioral Neuroscience Reports, 2015, 2, 234-245.	1.3	41
78	Topographic staging of tau positron emission tomography images. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 221-231.	2.4	41
79	Exercise prevents obesity-induced cognitive decline and white matter damage in mice. Neurobiology of Aging, 2019, 80, 154-172.	3.1	40
80	Deep Fusion of Brain Structure-Function in Mild Cognitive Impairment. Medical Image Analysis, 2021, 72, 102082.	11.6	37
81	Deep learning detection of informative features in tau PET for Alzheimer's disease classification. BMC Bioinformatics, 2020, 21, 496.	2.6	37
82	Identifying progressive imaging genetic patterns via multi-task sparse canonical correlation analysis: a longitudinal study of the ADNI cohort. Bioinformatics, 2019, 35, i474-i483.	4.1	36
83	A Novel Structure-Aware Sparse Learning Algorithm for Brain Imaging Genetics. Lecture Notes in Computer Science, 2014, 17, 329-336.	1.3	36
84	The effect of the top 20 Alzheimer disease risk genes on grayâ€matter density and FDG PET brain metabolism. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 53-66.	2.4	35
85	Comprehensive Gene- and Pathway-Based Analysis of Depressive Symptoms in Older Adults. Journal of Alzheimer's Disease, 2015, 45, 1197-1206.	2.6	33
86	FASTKD2 is associated with memory and hippocampal structure in older adults. Molecular Psychiatry, 2015, 20, 1197-1204.	7.9	33
87	Cognitive Dysfunction and Greater Visitâ€toâ€Visit Systolic Blood Pressure Variability. Journal of the American Geriatrics Society, 2013, 61, 2168-2173.	2.6	32
88	A novel SCCA approach via truncated <i> â,," </i> 1-norm and truncated group lasso for brain imaging genetics. Bioinformatics, 2018, 34, 278-285.	4.1	31
89	Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer's amyloid, tau and FDG PET status. Translational Psychiatry, 2021, 11, 585.	4.8	31
90	Targeted genetic analysis of cerebral blood flow imaging phenotypes implicates the INPP5D gene. Neurobiology of Aging, 2019, 81, 213-221.	3.1	30

#	Article	IF	CITATIONS
91	Tau-related white-matter alterations along spatially selective pathways. NeuroImage, 2021, 226, 117560.	4.2	30
92	Development and validation of language and visuospatial composite scores in ADNI. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12072.	3.7	29
93	Network-based analysis of genetic variants associated with hippocampal volume in Alzheimer's disease: a study of ADNI cohorts. BioData Mining, 2016, 9, 3.	4.0	28
94	Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease. BMC Medical Genomics, 2017, 10, 29.	1.5	28
95	Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1â€42 in Alzheimer's Disease Neuroimaging Initiative participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 94-98.	2.4	28
96	Dysregulated Fc gamma receptor–mediated phagocytosis pathway in Alzheimer's disease: network-based gene expression analysis. Neurobiology of Aging, 2020, 88, 24-32.	3.1	28
97	Associating Multi-Modal Brain Imaging Phenotypes and Genetic Risk Factors via a Dirty Multi-Task Learning Method. IEEE Transactions on Medical Imaging, 2020, 39, 3416-3428.	8.9	27
98	A rat head holder for simultaneous scanning of two rats in small animal PET scanners: Design, construction, feasibility testing and kinetic validation. Journal of Neuroscience Methods, 2009, 176, 24-33.	2.5	26
99	Identifying Multimodal Intermediate Phenotypes Between Genetic Risk Factors and Disease Status in Alzheimer's Disease. Neuroinformatics, 2016, 14, 439-452.	2.8	26
100	Tau Imaging in Alzheimer's Disease Diagnosis and Clinical Trials. Neurotherapeutics, 2017, 14, 62-68.	4.4	26
101	Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition. Brain Communications, 2020, 2, fcaa019.	3.3	26
102	Neuroimaging in aging and neurologic diseases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 191-227.	1.8	25
103	Multi-Task Sparse Canonical Correlation Analysis with Application to Multi-Modal Brain Imaging Genetics. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2021, 18, 227-239.	3.0	25
104	Cholinergic Enhancement of Brain Activation in Mild Cognitive Impairment during Episodic Memory Encoding. Frontiers in Psychiatry, 2013, 4, 105.	2.6	23
105	Hippocampal transcriptome-guided genetic analysis of correlated episodic memory phenotypes in Alzheimer's disease. Frontiers in Genetics, 2015, 6, 117.	2.3	23
106	Tissue-specific network-based genome wide study of amygdala imaging phenotypes to identify functional interaction modules. Bioinformatics, 2017, 33, 3250-3257.	4.1	23
107	Genomeâ€wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. Alzheimer's and Dementia, 2020, 16, 1213-1223.	0.8	23
108	Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. Translational Psychiatry, 2021, 11, 483.	4.8	23

#	Article	IF	CITATIONS
109	Genetic architecture of resilience of executive functioning. Brain Imaging and Behavior, 2012, 6, 621-633.	2.1	22
110	Memory concerns in the early Alzheimer's disease prodrome: Regional association with tau deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 322-331.	2.4	22
111	Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways. Scientific Reports, 2019, 9, 14498.	3.3	22
112	Serum metabolites associated with brain amyloid beta deposition, cognition and dementia progression. Brain Communications, 2021, 3, fcab139.	3.3	21
113	Sparse Bayesian Learning for Identifying Imaging Biomarkers in AD Prediction. Lecture Notes in Computer Science, 2010, 13, 611-618.	1.3	21
114	Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease. BMC Medical Genomics, 2016, 9, 30.	1.5	20
115	Identifying diagnosis-specific genotype–phenotype associations via joint multitask sparse canonical correlation analysis and classification. Bioinformatics, 2020, 36, i371-i379.	4.1	20
116	Hippocampal Surface Mapping of Genetic Risk Factors in AD via Sparse Learning Models. Lecture Notes in Computer Science, 2011, 14, 376-383.	1.3	20
117	Genome-wide association study of language performance in Alzheimer's disease. Brain and Language, 2017, 172, 22-29.	1.6	20
118	Hippocampal-subfield microstructures and their relation to plasma biomarkers in Alzheimer's disease. Brain, 2022, 145, 2149-2160.	7.6	20
119	Differences in Medication Use in the Alzheimer's Disease Neuroimaging Initiative. Drugs and Aging, 2010, 27, 677-686.	2.7	19
120	Optimizing differential identifiability improves connectome predictive modeling of cognitive deficits from functional connectivity in Alzheimer's disease. Human Brain Mapping, 2021, 42, 3500-3516.	3.6	18
121	Age at injury is associated with the longâ€ŧerm cognitive outcome of traumatic brain injuries. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 196-200.	2.4	17
122	Exome Chip Analysis Identifies Low-Frequency and Rare Variants in <i>MRPL38</i> for White Matter Hyperintensities on Brain Magnetic Resonance Imaging. Stroke, 2018, 49, 1812-1819.	2.0	17
123	Identification of exon skipping events associated with Alzheimer's disease in the human hippocampus. BMC Medical Genomics, 2019, 12, 13.	1.5	17
124	Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis. Alzheimer's Research and Therapy, 2020, 12, 93.	6.2	17
125	Regional imaging genetic enrichment analysis. Bioinformatics, 2020, 36, 2554-2560.	4.1	16
126	Sparse Bayesian multi-task learning for predicting cognitive outcomes from neuroimaging measures in Alzheimer's disease. , 2012, , .		15

#	Article	IF	CITATIONS
127	Bile acids targeted metabolomics and medication classification data in the ADNI1 and ADNIGO/2 cohorts. Scientific Data, 2019, 6, 212.	5.3	15
128	IDENTIFICATION OF DISCRIMINATIVE IMAGING PROTEOMICS ASSOCIATIONS IN ALZHEIMER'S DISEASE VIA A NOVEL SPARSE CORRELATION MODEL. , 2017, 22, 94-104.		14
129	Telomere Shortening in the Alzheimer's Disease Neuroimaging Initiative Cohort. Journal of Alzheimer's Disease, 2019, 71, 33-43.	2.6	14
130	GN-SCCA: GraphNet Based Sparse Canonical Correlation Analysis for Brain Imaging Genetics. Lecture Notes in Computer Science, 2015, 9250, 275-284.	1.3	14
131	Two-dimensional enrichment analysis for mining high-level imaging genetic associations. Brain Informatics, 2017, 4, 27-37.	3.0	13
132	Volumetric comparison of hippocampal subfields extracted from 4-minute accelerated vs. 8-minute high-resolution T2-weighted 3T MRI scans. Brain Imaging and Behavior, 2018, 12, 1583-1595.	2.1	13
133	Fast Multi-Task SCCA Learning with Feature Selection for Multi-Modal Brain Imaging Genetics. , 2018, 2018, 356-361.		13
134	Joint High-Order Multi-Task Feature Learning to Predict the Progression of Alzheimer's Disease. Lecture Notes in Computer Science, 2018, 11070, 555-562.	1.3	13
135	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. NeuroImage: Clinical, 2021, 30, 102660.	2.7	13
136	Rare variants in the splicing regulatory elements of EXOC3L4 are associated with brain glucose metabolism in Alzheimer's disease. BMC Medical Genomics, 2018, 11, 76.	1.5	12
137	Novel Markers of Angiogenesis in the Setting of Cognitive Impairment and Dementia. Journal of Alzheimer's Disease, 2020, 75, 959-969.	2.6	12
138	Identifying Associations Between Brain Imaging Phenotypes and Genetic Factors via a Novel Structured SCCA Approach. Lecture Notes in Computer Science, 2017, 10265, 543-555.	1.3	12
139	Cerebral hypometabolism and grey matter density in MAPT intron 10 +3 mutation carriers. American Journal of Neurodegenerative Disease, 2014, 3, 103-14.	0.1	12
140	Quantitative trait loci identification for brain endophenotypes via new additive model with random networks. Bioinformatics, 2018, 34, i866-i874.	4.1	11
141	Genome-wide Network-assisted Association and Enrichment Study of Amyloid Imaging Phenotype in Alzheimer's Disease. Current Alzheimer Research, 2020, 16, 1163-1174.	1.4	11
142	Multivariate genome wide association and network analysis of subcortical imaging phenotypes in Alzheimer's disease. BMC Genomics, 2020, 21, 896.	2.8	11
143	Building a surface atlas of hippocampal subfields from MRI scans using FreeSurfer, FIRST and SPHARM. , 2014, 2014, 813-816.		10
144	Detection of tau in Gerstmann-Strässler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET. Acta Neuropathologica Communications, 2018, 6, 114.	5.2	10

#	Article	IF	CITATIONS
145	A Graph-Based Integration of Multimodal Brain Imaging Data for the Detection of Early Mild Cognitive Impairment (E-MCI). Lecture Notes in Computer Science, 2013, 8159, 159-169.	1.3	10
146	Social Networks and Cognitive Reserve: Network Structure Moderates the Association Between Amygdalar Volume and Cognitive Outcomes. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2022, 77, 1490-1500.	3.9	10
147	Structured sparse CCA for brain imaging genetics via graph OSCAR. BMC Systems Biology, 2016, 10, 68.	3.0	9
148	Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex Penalty. Scientific Reports, 2017, 7, 14052.	3.3	9
149	Diagnosis Status Guided Brain Imaging Genetics Via Integrated Regression And Sparse Canonical Correlation Analysis. , 2019, 2019, 356-359.		9
150	Neurodegenerative Patterns of Cognitive Clusters of Early-Onset Alzheimer's Disease Subjects: Evidence for Disease Heterogeneity. Dementia and Geriatric Cognitive Disorders, 2019, 48, 131-142.	1.5	9
151	Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups. NeuroImage: Clinical, 2021, 31, 102725.	2.7	9
152	Identification of functional variants from whole-exome sequencing, combined with neuroimaging genetics. Molecular Psychiatry, 2013, 18, 739-739.	7.9	8
153	Identifying Candidate Genetic Associations with MRI-Derived AD-Related ROI via Tree-Guided Sparse Learning. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2019, 16, 1986-1996.	3.0	8
154	Integrative-omics for discovery of network-level disease biomarkers: a case study in Alzheimer's disease. Briefings in Bioinformatics, 2021, 22, .	6.5	8
155	PARP1 Gene Variation and Microglial Activity on [11C]PBR28 PET in Older Adults at Risk for Alzheimer's Disease. Lecture Notes in Computer Science, 2013, 8159, 150-158.	1.3	8
156	Longitudinal Genotype-Phenotype Association Study via Temporal Structure Auto-learning Predictive Model. Lecture Notes in Computer Science, 2017, 10229, 287-302.	1.3	8
157	The effect of reference panels and software tools on genotype imputation. AMIA Annual Symposium proceedings, 2011, 2011, 1013-8.	0.2	8
158	[(11)C]PiB PET in Gerstmann-StrÄ u ssler-Scheinker disease. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 84-93.	1.0	8
159	Imaging of alcoholâ€induced dopamine release in rats:Preliminary findings with [¹¹ C]raclopride PET. Synapse, 2011, 65, 929-937.	1.2	7
160	Volumetric GWAS of medial temporal lobe structures identifies an ERC1 locus using ADNI high-resolution T2-weighted MRI data. Neurobiology of Aging, 2020, 95, 81-93.	3.1	7
161	Temporal stability of the ventral attention network and general cognition along the Alzheimer's disease spectrum. NeuroImage: Clinical, 2021, 31, 102726.	2.7	7
162	Association of the top 20 Alzheimer's disease risk genes with [¹⁸ F]flortaucipir PET. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12308.	2.4	7

#	Article	IF	CITATIONS
163	Sparse Canonical Correlation Analysis via truncated â,," <inf>1</inf> -norm with application to brain imaging genetics. , 2016, 2016, 707-711.		6
164	Codon bias among synonymous rare variants is associated with Alzheimer's disease imaging biomarker. , 2018, , .		6
165	Predicting progressions of cognitive outcomes via high-order multi-modal multi-task feature learning. , 2018, , .		6
166	Longitudinal Genotype–Phenotype Association Study through Temporal Structure Auto-Learning Predictive Model. Journal of Computational Biology, 2018, 25, 809-824.	1.6	6
167	Codon bias among synonymous rare variants is associated with Alzheimer's disease imaging biomarker. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2018, 23, 365-376.	0.7	6
168	Genetic variation affecting exon skipping contributes to brain structural atrophy in Alzheimer's disease. AMIA Summits on Translational Science Proceedings, 2018, 2017, 124-131.	0.4	6
169	Surface-based morphometric analysis of hippocampal subfields in mild cognitive impairment and Alzheimer's disease. , 2015, 2015, .		5
170	Multiple incomplete views clustering via non-negative matrix factorization with its application in Alzheimer's disease analysis. , 2018, , .		5
171	Neuroimaging Advances in Neurologic and Neurodegenerative Diseases. Neurotherapeutics, 2021, 18, 659-660.	4.4	5
172	Tau deposition and structural connectivity demonstrate differential association patterns with neurocognitive tests. Brain Imaging and Behavior, 2022, 16, 702-714.	2.1	5
173	Head injury is associated with tau deposition on PET in MCI and AD patients. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12230.	2.4	5
174	Network-Guided Sparse Learning for Predicting Cognitive Outcomes from MRI Measures. Lecture Notes in Computer Science, 2013, 8159, 202-210.	1.3	5
175	Transcriptome-Guided Imaging Genetic Analysis via a Novel Sparse CCA Algorithm. Lecture Notes in Computer Science, 2017, 10551, 220-229.	1.3	5
176	Multimodal Neuroimaging Predictors for Cognitive Performance Using Structured Sparse Learning. Lecture Notes in Computer Science, 2012, , 1-17.	1.3	4
177	DIAGNOSIS-GUIDED METHOD FOR IDENTIFYING MULTI-MODALITY NEUROIMAGING BIOMARKERS ASSOCIATED WITH GENETIC RISK FACTORS IN ALZHEIMER'S DISEASE. , 2016, , .		4
178	Brain explorer for connectomic analysis. Brain Informatics, 2017, 4, 253-269.	3.0	4
179	Joint exploration and mining of memory-relevant brain anatomic and connectomic patterns via a three-way association model. , 2018, 2018, 6-9.		4
180	MIND food and speed of processing training in older adults with low education, the MINDSpeed Alzheimer's disease prevention pilot trial. Contemporary Clinical Trials, 2019, 84, 105814.	1.8	4

SHANNON LEIGH RISACHER

#	Article	IF	CITATIONS
181	Mining Regional Imaging Genetic Associations via Voxel-wise Enrichment Analysis. , 2019, 2019, .		4
182	Cognitive biomarker prioritization in Alzheimer's Disease using brain morphometric data. BMC Medical Informatics and Decision Making, 2020, 20, 319.	3.0	4
183	Neuroimaging of Alzheimer's Disease, Mild Cognitive Impairment, and Other Dementias. , 2011, , 309-339.		4
184	Integrated Visualization of Human Brain Connectome Data. Lecture Notes in Computer Science, 2015, 9250, 295-305.	1.3	4
185	Predicting Interrelated Alzheimer's Disease Outcomes via New Self-learned Structured Low-Rank Model. Lecture Notes in Computer Science, 2017, 10265, 198-209.	1.3	4
186	Prescribing cholinesterase inhibitors in mild cognitive impairment—Observations from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12168.	3.7	4
187	IC-01-04: Neuroinflammation and amyloid deposition: Concurrent [11 C]PBR28 and [11 C]PIB PET imaging in patients with Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints. , 2010, 6, S3-S4.		3
188	P4-008: Mapre2 as a novel Alzheimer's disease target gene from gwas of CSF amyloid beta 1-42, tau and hyperphosphorylated tau in the ADNI cohort. , 2015, 11, P767-P768.		3
189	Structural Brain Network Constrained Neuroimaging Marker Identification for Predicting Cognitive Functions. Lecture Notes in Computer Science, 2013, 23, 536-547.	1.3	3
190	DIAGNOSIS-GUIDED METHOD FOR IDENTIFYING MULTI-MODALITY NEUROIMAGING BIOMARKERS ASSOCIATED WITH GENETIC RISK FACTORS IN ALZHEIMER'S DISEASE. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2016, 21, 108-19.	0.7	3
191	P2â€098: Whole Brain Surfaceâ€Based Analysis Identified Brain Atrophy Associated with SNPS in <i>FRMD6</i> Linked to Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P648.	0.8	2
192	IC-03-03: Cognitive Complaints in Older Adults at Risk For Alzheimer's Disease are Associated with Altered Resting State Networks. , 2016, 12, P10-P11.		2
193	ICâ€Pâ€032: IMPROVING PREDICTION OF COGNITIVE OUTCOMES FROM FUNCTIONAL CONNECTIVITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P38.	0.8	2
194	Prioritization of Cognitive Assessments in Alzheimer's Disease via Learning to Rank using Brain Morphometric Data. , 2019, 2019, .		2
195	Transcriptomic profiles underlying functional brain networks at different stages of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046163.	0.8	2
196	A novel MRI contrast weighted ratio method for measuring myelin in older adults at risk for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046297.	0.8	2
197	Associations between Cortical Thickness and Metamemory in Alzheimer's Disease. Brain Imaging and Behavior, 2022, , 1.	2.1	2
198	Integrative analysis of eQTL and GWAS summary statistics reveals transcriptomic alteration in Alzheimer brains. BMC Medical Genomics, 2022, 15, 93.	1.5	2

#	Article	IF	CITATIONS
199	O3-03-01: Genome-wide association study of CSF biomarkers amyloid beta 1-42, tau and tau phosphorylated at threonine 181 in the ADNI cohort. , 2010, 6, S129-S129.		1
200	O3-03-02: TWO-YEAR LONGITUDINAL CHANGE IN AMYLOID DEPOSITION, GLUCOSE METABOLISM, AND HIPPOCAMPAL ATROPHY IN ADNI-2 PARTICIPANTS: RELATION TO GENETIC RISK. , 2014, 10, P211-P212.		1
201	IC-P-094: ALTERED FMRI ACTIVATION PATTERN DURING VISUAL SCENE ENCODING IN AFFECTED AND NON-AFFECTED CARRIERS OF PSEN1 AND APP MUTATIONS. , 2014, 10, P53-P53.		1
202	IC-P-042: Influence of rare reelin variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer's disease. , 2015, 11, P36-P36.		1
203	P1-201: Genetic findings using ADNI multimodal quantitative phenotypes: A 2014 update. , 2015, 11, P426-P426.		1
204	O3-13-04: Genome-wide rare variant analysis identifies candidate genes significantly associated with composite scores for memory. , 2015, 11, P251-P252.		1
205	Two-Dimensional Enrichment Analysis for Mining High-Level Imaging Genetic Associations. Lecture Notes in Computer Science, 2015, 9250, 115-124.	1.3	1
206	Building a surface atlas of hippocampal subfields from high resolution T2-weighted MRI scans using landmark-free surface registration. , 2016, 2016, .		1
207	ICâ€Pâ€092: Elevated Cerebral Blood Flow in Participants with Subjective Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P70.	0.8	1
208	P2â€074: A Metaâ€Analysis Identifies <i>ADORA2A</i> Associated with Hippocampal Volume in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P636.	0.8	1
209	O5â€01â€04: EXAMINING THE EFFECT OF THE TOP 20 ALZHEIMER'S DISEASE RISK VARIANTS ON BRAIN AMYLOIDOSIS, STRUCTURAL ATROPHY AND METABOLISM. Alzheimer's and Dementia, 2016, 12, P376.	0.8	1
210	A New Statistical Image Analysis Approach and Its Application to Hippocampal Morphometry. Lecture Notes in Computer Science, 2016, 9805, 302-310.	1.3	1
211	Network-based genome wide study of hippocampal imaging phenotype in Alzheimer's Disease to identify functional interaction modules. , 2017, 2017, 6170-6174.		1
212	[P1–449]: RESTING STATE NETWORK MODULARITY ALONG THE PRODROMAL LATE ONSET ALZHEIMER's DISEASE CONTINUUM. Alzheimer's and Dementia, 2017, 13, P457.	0.8	1
213	Sixâ€month decline in language, but not other cognitive domains, identifies increased risk of conversion from MCI to AD in ADNI. Alzheimer's and Dementia, 2020, 16, e045357.	0.8	1
214	A Dirty Multi-task Learning Method for Multi-modal Brain Imaging Genetics. Lecture Notes in Computer Science, 2019, , 447-455.	1.3	1
215	O4â€01â€01: Classification of MCI and Alzheimer's disease from CSF biomarkers: An ADNI study of Aß, tau and Pâ€ŧau versus 83 proteomic analytes. Alzheimer's and Dementia, 2012, 8, P609.	0.8	0
216	IC-O1-03: Hippocampal transcriptome-guided gene-gene interaction of memory phenotype in MCI and		0

Alzheimer's disease. , 2013, 9, P4-P4.

#	Article	IF	CITATIONS
217	P3-018: INFLUENCE OF RARE PSEN1 VARIANTS ON QUANTITATIVE STRUCTURAL IMAGING AND CSF PHENOTYPES IN LATE ONSET ALZHEIMER'S DISEASE. , 2014, 10, P633-P633.		0
218	IC-P-172: GENOME-WIDE PROTEIN INTERACTION GUIDED EPISTATIC ANALYSIS ON MEMORY PERFORMANCE: AN ADNI STUDY. , 2014, 10, P95-P96.	١	0
219	IC-P-173: EFFECTS OF NEWLY IDENTIFIED TOP AD CANDIDATE GENES ON MEMORY PERFORMANCE: SNP, GENE AND EPISTASIS ANALYSES IN ADNI. , 2014, 10, P96-P97.		0
220	P3-102: VISUAL AND AUDITORY CHANGES ARE ASSOCIATED WITH NEUROIMAGING BIOMARKERS DURING PRODROMAL STAGES OF ALZHEIMER'S DISEASE. , 2014, 10, P665-P666.		0
221	P1-230: EFFECTS OF NEWLY IDENTIFIED TOP AD CANDIDATE GENES ON MEMORY PERFORMANCE: SNP, GENE, AND EPISTASIS ANALYSES IN ADNI. , 2014, 10, P388-P388.		0
222	IC-P-095: TWO-YEAR LONGITUDINAL CHANGE IN AMYLOID DEPOSITION, GLUCOSE METABOLISM, AND HIPPOCAMPAL ATROPHY IN ADNI-2 PARTICIPANTS: RELATION TO GENETIC RISK. , 2014, 10, P53-P54.		0
223	IC-P-097: VISUAL AND AUDITORY CHANGES ARE ASSOCIATED WITH NEUROIMAGING BIOMARKERS DURING PRODROMAL STAGES OF ALZHEIMER'S DISEASE. , 2014, 10, P54-P55.		0
224	O1-01-03: COMPARATIVE ANALYSIS OF PIB IN VIVO WITH 6-CN-PIB AND AB-IMMUNOHISTOCHEMISTRY POSTMORTEM IN FAMILIAL ALZHEIMER'S DISEASE ASSOCIATED WITH THE PSEN1 I229F MUTATION. , 2014, 10, P129-P129.		0
225	P4-105: ALTERED FMRI ACTIVATION PATTERN DURING VISUAL SCENE ENCODING IN AFFECTED AND NON-AFFECTED CARRIERS OF PSEN1 AND APP MUTATIONS. , 2014, 10, P822-P823.		0
226	IC-P-174: RARE VARIANT IN PLD3 IS ASSOCIATED WITH ALZHEIMER'S PATTERN OF NEURODEGENERATIVE CHANGES. , 2014, 10, P97-P97.		0
227	P3-024: NEXT-GENERATION SEQUENCING OF THE BCHE LOCUS IDENTIFIES A FUNCTIONAL SNP ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS AND AGE OF ONSET. , 2014, 10, P636-P636.		0
228	P4-054: ASSOCIATION OF PLASMA LEPTIN/ADIPONECTIN RATIO IN MEN WITH CSF BIOMARKERS IN THE ADNI-1 COHORT. , 2014, 10, P801-P802.		0
229	O2-03-01: INCREASED AMYLOID DEPOSITION IN OLDER ADULTS AT RISK FOR PROGRESSION TO ALZHEIMER'S DISEASE DUE TO GENETIC BACKGROUND AND/OR THE PRESENCE OF SIGNIFICANT MEMORY CONCERNS. , 2014, 10, P167-P167.		0
230	IC-P-096: INCREASED AMYLOID DEPOSITION IN OLDER ADULTS AT RISK FOR PROGRESSION TO ALZHEIMER'S DISEASE DUE TO GENETIC BACKGROUND AND/OR THE PRESENCE OF SIGNIFICANT MEMORY CONCERNS. , 2014, 10, P54-P54.		0
231	P1-213: GENOME-WIDE PROTEIN INTERACTION-GUIDED EPISTATIC ANALYSIS ON MEMORY PERFORMANCE: AN ADNI STUDY. , 2014, 10, P381-P382.		0
232	IC-P-032: COMPARATIVE ANALYSIS OF PIB IN VIVO WITH 6-CN-PIB AND AÎ ² -IMMUNOHISTOCHEMISTRY POSTMORTEM IN FAMILIAL ALZHEIMER DISEASE ASSOCIATED WITH THE PSEN1 I229F MUTATION. , 2014, 10, P20-P21.		0
233	P3-017: ASSOCIATION ANALYSIS OF RARE VARIANTS NEAR THE APOE REGION WITH CEREBROSPINAL FLUID (CSF) BIOMARKERS OF ALZHEIMER'S DISEASE. , 2014, 10, P632-P633.		0
234	P3-019: RARE VARIANT IN PLD3 IS ASSOCIATED WITH ALZHEIMER'S PATTERN OF NEURODEGENERATIVE CHANGES. , 2014, 10, P634-P634.		0

#	Article	IF	CITATIONS
235	IC-P-138: POSTERIOR CEREBRAL ATROPHY ASSOCIATED WITH THE PSEN1 I229F MUTATION. , 2014, 10, P78-P7	'9.	0
236	P4-083: THE COGNITIVE CHANGE INDEX AS A MEASURE OF SUBJECTIVE COGNITIVE DECLINE AND INFORMANT PERCEPTION: RELATION TO TEST PERFORMANCE. , 2014, 10, P813-P813.		0
237	P4-146: POSTERIOR CEREBRAL ATROPHY ASSOCIATED WITH THE PSEN1 I229F MUTATION. , 2014, 10, P842-P8	342.	0
238	P4-237: WHOLE GENE-BASED ASSOCIATION OF BASELINE PLASMA HOMOCYSTEINE IN THE ADNI-1 COHORT. , 2014, 10, P873-P874.		0
239	P3-134: Association of eye disease with increased diffusivity in the sagittal stratum. , 2015, 11, P675-P675.		0
240	P2-088: Differences in neuropsychological performance between cognitively normal individuals with or without significant memory concerns using the cognitive change index. , 2015, 11, P517-P517.		0
241	P2-132: Association of cerebral microhemorrhages with amyloid deposition and hyperlipidemia. , 2015, 11, P534-P535.		0
242	P2-204: Model-based analysis of continuous performance memory assessment demonstrates mechanisms underlying deficits in mild cognitive impairment. , 2015, 11, P570-P571.		0
243	P3-014: Influence of rare RELN variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer's disease. , 2015, 11, P624-P625.		0
244	P4-191: Gwas identifies gli3 as a novel gene for language deficits and cortical changes in older adults at-risk for Alzheimer's disease. , 2015, 11, P853-P853.		0
245	P1-193: Anticholinergic medication use in older adults is associated with memory and hippocampal volume. , 2015, 11, P422-P422.		0
246	IC-P-035: Effect of hypertension and antihypertensive medication on executive function, brain atrophy, and white matter hyperintensities. , 2015, 11, P32-P33.		0
247	IC-P-055: Glucose hypometabolism in gerstmann-strässler-scheinker patients with the F198S mutation. , 2015, 11, P43-P43.		0
248	IC-P-034: Anticholinergic medication use in older adults is associated with memory and hippocampal volume. , 2015, 11, P32-P32.		0
249	IC-P-036: Association of eye disease with increased diffusivity in the sagittal stratum. , 2015, 11, P33-P33.		0
250	P1-213: Influence of history of traumatic brain injury on age at onset of cognitive impairment in MCI and Alzheimer's disease. , 2015, 11, P432-P432.		0
251	P4-197: Gene expression profiling identifies altered networks in late-onset Alzheimer's disease: Immune response and mitochondrial process. , 2015, 11, P855-P856.		0
252	O4-05-01: Gwas of longitudinal amyloid PET identifies IL1RAP as a new potential Alzheimer's disease target. , 2015, 11, P277-P278.		0

#	Article	IF	CITATIONS
253	IC-P-037: Association of cerebral microhemorrhages with amyloid deposition and hyperlipidemia. , 2015, 11, P33-P34.		0
254	O1-04-04: Effect of hypertension and antihypertensive medication on executive function, brain atrophy, and white matter hyperintensities. , 2015, 11, P133-P134.		0
255	O4-10-04: Extension of a validation study of the cognitive change index (CCI) tool to measure self and informant perception of cognitive decline: Relation to test performance. , 2015, 11, P294-P294.		0
256	P1-002: Transcriptome-guided neurogenesis gene pathway variation is associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. , 2015, 11, P336-P337.		0
257	P1-009: The nav2 (neuron navigator 2) gene as a common genetic influence across correlated episodic memory performances. , 2015, 11, P339-P340.		0
258	P2-124: Glucose hypometabolism in gerstmann-strÃ ¤ ssler-scheinker patients with the F198S mutation. , 2015, 11, P530-P531.		0
259	P4-195: Pathway-based gene analysis identifies vegfa as a gene associated with cerebral blood flow in Alzheimer's disease. , 2015, 11, P855-P855.		0
260	IC-P-094: Association Between N-Back Working Memory Activation on FMRI and Cognitive Assessment of Executive Function. , 2016, 12, P72-P72.		0
261	P1-259: The Ratio of Cortical and Hippocampal Volumes Predicts Rate of Clinical Decline in Alzheimer's Disease. , 2016, 12, P510-P510.		0
262	ICâ€Pâ€156: Scene Encoding FMRI in Subjective Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P116.	0.8	0
263	P4â€173: Elevated Cerebral Blood Flow in Participants with Subjective Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1084.	0.8	0
264	O1â€12â€02: Identification of Discriminative Brain Imaging and Genomic Associations: an Alzheimer's Disease Study. Alzheimer's and Dementia, 2016, 12, P205.	0.8	0
265	ICâ€02â€01: The Effects of The Top 20 Alzheimer's Disease Risk Genes on Brain Atrophy. Alzheimer's and Dementia, 2016, 12, P4.	0.8	0
266	ICâ€₽â€059: Examining The Effect of The Top 20 Ad Risk Variants on Brain Amyloidosis, Structural Atrophy and Metabolism. Alzheimer's and Dementia, 2016, 12, P47.	0.8	0
267	IC-P-061: Alzheimer's Disease Risk Genes Can Predict Brain Amyloidosis. , 2016, 12, P49-P50.		0
268	P1â€261: Association of [¹⁸ F]AVâ€1451 TAU Markers with Cognitive and Neurodegeneration Measures: Preliminary Analysis in The Adni Cohort. Alzheimer's and Dementia, 2016, 12, P512.	0.8	0
269	ICâ€₽â€072: Gene Expression Of ABCA7 Dysregulated in Peripheral Blood is Associated With Decreased Metabolic Activity in Hippocampus. Alzheimer's and Dementia, 2016, 12, P56.	0.8	0
270	ICâ€Pâ€074: Genomeâ€Wide Metaâ€Analysis of Transcriptome Profiling Identifies Novel Dysregulated Genes Implicated in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P58.	0.8	0

#	Article	IF	CITATIONS
271	ICâ€Pâ€075: The Growth and Impact of ADNI Genetics Publications as Measured by Science Mapping. Alzheimer's and Dementia, 2016, 12, P60.	0.8	0
272	IC-P-096: The Ratio of Cortical and Hippocampal Volumes Predicts Rate of Clinical Decline in Alzheimer's Disease. , 2016, 12, P73-P73.		0
273	IC-P-109: Plasma TAU Levels in Mild Cognitive Impairment and Alzheimer's Disease. , 2016, 12, P82-P83.		0
274	P2â€233: Alzheimer's Disease Risk Genes Can Predict Brain Amyloidosis. Alzheimer's and Dementia, 2016, 12, P712.	0.8	0
275	P2â€253: The Effects of the Top 20 Alzheimer's Disease Risk Genes on Brain Atrophy. Alzheimer's and Dementia, 2016, 12, P722.	0.8	0
276	P2â€258: The Growth and Impact of ADNI Genetics Publications as Measured by Science Mapping. Alzheimer's and Dementia, 2016, 12, P725.	0.8	0
277	P2â€264: Association between Nâ€Back Working Memory Activation on FMRI and Cognitive Assessment of Executive Function. Alzheimer's and Dementia, 2016, 12, P728.	0.8	0
278	P2â€⊋75: SCENE ENCODING FMRI IN SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2016, 12, P73	40.8	0
279	P3â€087: Gene Expression of <i>ABCA7</i> Dysregulated in Peripheral Blood is Associated With Decreased Metabolic Activity in Hippocampus. Alzheimer's and Dementia, 2016, 12, P851.	0.8	0
280	ICâ€Pâ€154: Association of The Cognitive Change Index With Hippocampal Subfield Volumes. Alzheimer's and Dementia, 2016, 12, P114.	0.8	0
281	ICâ€Pâ€175: Hybrid Diffusion Imaging (HYDI) of White Matter Changes in Older Adults With Subjective Cognitive Decline (SCD): Assessment of Orientation Dispersion and Axonal Density. Alzheimer's and Dementia, 2016, 12, P127.	0.8	0
282	P4-166: Association of the Cognitive Change Index With Hippocampal Subfield Volumes. , 2016, 12, P1080-P1081.		0
283	P4â€⊋22: How Age at Injury Affects the Longâ€Term Outcomes of Traumatic Brain Injury. Alzheimer's and Dementia, 2016, 12, P1113.	0.8	0
284	IC-P-205: Relationship Between [18 F]Av-1451 Binding and Antecedent Amyloid Deposition, Glucose Hypometabolism and Atrophy Measures: Preliminary Analysis in the ADNI Cohort. , 2016, 12, P146-P147.		0
285	ICâ€Pâ€207: Association of [¹⁸ F]Avâ€1451 TAU Markers with Cognitive and Neurodegeneration Measures: Preliminary Analysis in the ADNI Cohort. Alzheimer's and Dementia, 2016, 12, P147.	0.8	0
286	F1-02-02: Genetic Influence on Levels of Targeted Metabolites Associated with Alzheimer's Disease. , 2016, 12, P164-P165.		0
287	O1â€13â€04: Effects of Cortical Amyloid b Deposition on the Incidence and Prevalence of Neuropsychiatric Behaviors in the Elderly. Alzheimer's and Dementia, 2016, 12, P210.	0.8	0
288	O2-06-02: Genome-Wide Meta-Analysis of Transcriptome Profiling Identifies Novel Dysregulated Genes Implicated in Alzheimer's Disease. , 2016, 12, P238-P239.		0

#	Article	IF	CITATIONS
289	O2â€10â€01: Genomeâ€Wide Association Analysis of Hippocampal Volume Identifies Enrichment of Neurogenesisâ€Related Pathways. Alzheimer's and Dementia, 2016, 12, P250.	0.8	0
290	O3â€02â€02: Relationship Between [¹⁸ F]AVâ€1451 Binding and Antecedent Amyloid Deposition, Glucose Hypometabolism and Atrophy Measures: Preliminary Analysis in the Adni Cohort. Alzheimer's and Dementia, 2016, 12, P282.	0.8	0
291	O4â€10â€04: Plasma TAU Levels in Mild Cognitive Impairment and Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P358.	0.8	0
292	P4-344: Volumetric Comparison of Automatically Segmented Hippocampal Subfields From 4-Min Accelerated Versus 8-Min T2-Weighted 3T Mri Scans. , 2016, 12, P1167-P1167.		0
293	Unraveling the Biologic Basis for Domain-Specific Cognitive Decline. American Journal of Geriatric Psychiatry, 2017, 25, 741-743.	1.2	0
294	[ICâ€₽â€084]: VISUAL LEARNING ON THE COGSTATE BATTERY IS ASSOCIATED WITH AMYLOID, TAU, AND NEURODEGENERATION IN COGNITIVELY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P68.	0.8	0
295	[P4–420]: DEVELOPMENT OF A TAU BIOLOGICAL NETWORK FOR GENETIC ANALYSIS OF TAUOPATHIES. Alzheimer's and Dementia, 2017, 13, P1492.	0.8	0
296	[ICâ€01–04]: A ROBUST, SIMPLIFIED BRAAKâ€TYPE CLASSIFICATION SCHEME FOR FLORTAUCIPIR Fâ€18 TAU F IMAGES. Alzheimer's and Dementia, 2017, 13, P3.	'ET 0.8	0
297	[ICâ€₽â€056]: <i>ADORA2A</i> POLYMORPHISM IS ASSOCIATED WITH CEREBRAL BLOOD FLOW IN MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P46.	0.8	0
298	[P2–356]: COMPARING IMAGING PHENOTYPES OF AMNESTIC EARLY VERSUS LATEâ€ONSET AMYLOIDâ€POSIT MILD COGNITIVE IMPAIRMENT AND DEMENTIA ADNI SUBJECTS. Alzheimer's and Dementia, 2017, 13, P759.	IVE 0.8	0
299	[P2–364]: VISUAL LEARNING ON THE COGSTATE BATTERY IS ASSOCIATED WITH AMYLOID, TAU, AND NEURODEGENERATION IN COGNITIVELY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P764.	0.8	0
300	[P2–417]: LANGUAGE FLUENCY PREDICTS RESTING STATE NETWORK CONNECTIVITY PATTERN. Alzheimer's and Dementia, 2017, 13, P793.	0.8	0
301	[P2–582]: ANTICHOLINERGIC MEDICATION USE IS ASSOCIATED WITH REDUCED FMRI ACTIVITY DURING VISUAL EPISODIC ENCODING IN COGNITIVELY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P870.	0.8	0
302	[P3–310]: OPTIMIZING COGNITIVE CHANGE INDEX CUTOFFS BASED ON COGNITIVE DECLINE AND BIOMARKER POSITIVITY IN COGNITIVELY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P1065.	0.8	0
303	[P4–224]: AXONAL DENSITY IS ASSOCIATED WITH SUBJECTIVE COGNITIVE DECLINE (SCD) IN OLDER ADULTS ASSESSED USING THE COGNITIVE CHANGE INDEX. Alzheimer's and Dementia, 2017, 13, P1355.	0.8	0
304	[P1–151]: <i>VEGFA</i> IS ASSOCIATED WITH CEREBRAL BLOOD FLOW AND WHITE MATTER HYPERINTENSITY IN MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P300.	0.8	0
305	[P4â€"386]: COMPARING IMAGING PHENOTYPES OF AMNESTIC EARLY―VERSUS LATEâ€ONSET AMYLOIDâ€NEG MILD COGNITIVE IMPAIRMENT AND DEMENTIA ADNI SUBJECTS. Alzheimer's and Dementia, 2017, 13, P1440.	CATIVE 0.8	0
306	[ICâ€Pâ€027]: LANGUAGE FLUENCY PREDICTS RESTING STATE NETWORK CONNECTIVITY PATTERN. Alzheimer's and Dementia, 2017, 13, P25.	0.8	0

#	Article	IF	CITATIONS
307	[ICâ€Pâ€099]: NEURODEGENERATIVE PATTERNS OF COGNITIVE CLUSTERS OF EARLY ONSET AD SUBJECTS: EVIDENCE FOR DISEASE HETEROGENEITY. Alzheimer's and Dementia, 2017, 13, P75.	0.8	0
308	[ICâ€Pâ€105]: COMPARING IMAGING PHENOTYPES OF AMNESTIC EARLY―VERSUS LATEâ€ONSET AMYLOIDâ€P MILD COGNITIVE IMPAIRMENT AND DEMENTIA ADNI SUBJECTS. Alzheimer's and Dementia, 2017, 13, P80.	OSIŢIVE	0
309	[ICâ€Pâ€212]: ANTICHOLINERGIC MEDICATION USE IS ASSOCIATED WITH REDUCED FMRI ACTIVITY DURING VISI EPISODIC ENCODING IN COGNITIVELY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P153.	JAL 0.8	Ο
310	[ICâ€Pâ€213]: PATHOLOGY IN THE EARLY ALZHEIMER'S PRODROME: SELF AND INFORMANT COGNITIVE CONCER SHOW DIFFERENT PATTERNS OF ASSOCIATION WITH TAU DEPOSITION ON [¹⁸ F]FLORTAUCIPIR PET IN AMYLOIDâ€POSITIVE OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P153.	2NS 0.8	0
311	[ICâ€Pâ€214]: OPTIMIZING COGNITIVE CHANGE INDEX CUTOFFS BASED ON COGNITIVE DECLINE AND BIOMARK POSITIVITY IN COGNITIVELY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2017, 13, P154.	ER 0.8	0
312	[ICâ€₽â€215]: VISUAL CONTRAST SENSITIVITY IS ASSOCIATED WITH AMYLOID AND TAU DEPOSITION. Alzheimer and Dementia, 2017, 13, P154.	^{'S} 0.8	0
313	[ICâ€Pâ€216]: COMPARING IMAGING PHENOTYPES OF AMNESTIC EARLY VERSUS LATEâ€ONSET AMYLOIDâ€NEC MILD COGNITIVE IMPAIRMENT AND DEMENTIA ADNI SUBJECTS. Alzheimer's and Dementia, 2017, 13, P155.	GATIVE 0.8	0
314	[ICâ€02–04]: AXONAL DENSITY IS ASSOCIATED WITH SUBJECTIVE COGNITIVE DECLINE (SCD) IN OLDER ADULT ASSESSED USING THE COGNITIVE CHANGE INDEX. Alzheimer's and Dementia, 2017, 13, P6.	0.8	0
315	[P1–286]: VISUAL CONTRAST SENSITIVITY IS ASSOCIATED WITH AMYLOID AND TAU DEPOSITION. Alzheimer's and Dementia, 2017, 13, P360.	0.8	0
316	[P2–111]: <i>ADORA2A</i> POLYMORPHISM IS ASSOCIATED WITH CEREBRAL BLOOD FLOW IN MILD COGNITIVE IMPAIRMENT (MCI) AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P649.	0.8	0
317	[P2–220]: GENETIC FINDINGS USING ADNI MULTIMODAL QUANTITATIVE PHENOTYPES: A 2016 UPDATE. Alzheimer's and Dementia, 2017, 13, P694.	0.8	0
318	[F1–02–04]: INTEGRATING MULTIâ€MODALITY IMAGING AND MULTIâ€LAYER â€OMICS TO ADVANCE THE SY BIOLOGY OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P175.	'STEMS	0
319	[O1–11–02]: GENOMEâ€WIDE ASSOCIATION ANALYSIS OF TAU ACCUMULATION IDENTIFIES ENRICHMENT (NEUROGENESISâ€RELATED PATHWAYS. Alzheimer's and Dementia, 2017, 13, P217.	ОҒ 0.8	0
320	[O3–03–02]: NEURODEGENERATIVE PATTERNS OF COGNITIVE CLUSTERS OF EARLY ONSET AD SUBJECTS: EVIDENCE FOR DISEASE HETEROGENEITY. Alzheimer's and Dementia, 2017, 13, P901.	0.8	0
321	[O4–07–05]: PATHOLOGY IN THE EARLY ALZHEIMER'S PRODROME: SELF AND INFORMANT COGNITIVE CONCERNS SHOW DIFFERENT PATTERNS OF ASSOCIATION WITH TAU DEPOSITION ON [¹⁸ F]FLORTAUCIPIR PET IN AMYLOIDâ€POSITIVE OLDER ADULTS. Alzheimer's and Dementia, 2017, 13. P1245.	0.8	0
322	[P4–421]: ELEVATED PLASMA NEUROFILAMENT LIGHT CHAIN IS ASSOCIATED WITH REDUCED GREY MATTER DENSITY IN AD AND MCI. Alzheimer's and Dementia, 2017, 13, P1493.	0.8	0
323	2307. Journal of Clinical and Translational Science, 2017, 1, 6-6.	0.6	0
324	P2â€459: THE COGNITIVE CHANGE INDEX IS ASSOCIATED WITH TAU DEPOSITION ON [¹⁸ F]FLORTAUCIPIR. Alzheimer's and Dementia, 2018, 14, P896.	0.8	0

#	Article	IF	CITATIONS
325	ICâ€Pâ€105: LONGITUDINAL PATTERNS OF DECLINE IN SUBTYPES OF AMNESTIC EARLY ONSET AD. Alzheimer's a Dementia, 2018, 14, P90.	nd 0.8	0
326	P4â€099: MULTIVARIATE CLUSTER PROFILING OF AMYLOID BETA, TAU, NEURODEGENERATION AND VASCULAR (ATNV) BIOMARKERS IN THE ADNI COHORT: IMPLICATIONS FOR COGNITION, –OMICS AND CLINICAL TRIALS. Alzheimer's and Dementia, 2018, 14, P1475.	0.8	0
327	ICâ€Pâ€108: COMBINATORIAL SENSORY MODALITY ASSESSMENT IN PRODROMAL ALZHEIMER'S DISEASE: RELATO MRI AND AMYLOID AND TAU PET. Alzheimer's and Dementia, 2018, 14, P92.	FIQN 8.8	0
328	P2â€⊋53: <i>EP300</i> IS ASSOCIATED WITH ALTERED BILE ACIDS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P772.	0.8	0
329	ICâ€Pâ€109: THE COGNITIVE CHANGE INDEX IS ASSOCIATED WITH TAU DEPOSITION ON [¹⁸ F]FLORTAUCIPIR. Alzheimer's and Dementia, 2018, 14, P93.	0.8	0
330	P1â€⊋96: COMBINATORIAL SENSORY MODALITY ASSESSMENT IN PRODROMAL ALZHEIMER'S DISEASE: RELATIO TO MRI AND AMYLOID AND TAU PET. Alzheimer's and Dementia, 2018, 14, P401.	N _{0.8}	0
331	P3â€618: HIGH RED MEAT INTAKE IS ASSOCIATED WITH INCREASED TAU ON [¹⁸ F]FLORTAUCIPIR P AND POORER MEMORY. Alzheimer's and Dementia, 2018, 14, P1367.	ЕТ 0.8	0
332	P2â€435: SEPARATION OF FUNCTIONAL CONNECTOMES ACROSS THE AD SPECTRUM BASED ON DISEASE SENSITIVE PRINCIPAL COMPONENTS. Alzheimer's and Dementia, 2018, 14, P879.	0.8	0
333	ICâ€Pâ€219: [18F]â€AVâ€1451 BINDING PROFILE IN EARLY AND LATEâ€ONSET ALZHEIMER'S DISEASE AND SUSI NONâ€ALZHEIMER PATHOPHYSIOLOGY. Alzheimer's and Dementia, 2018, 14, P178.	PECTED	0
334	P1â€143: MULTIVARIATE GENOMEâ€WIDE ASSOCIATION STUDY OF CSF BIOMARKERS FOR ALZHEIMER'S DISEAS IDENTIFIES VARIANTS IN HLA CLASS I REGION PROVIDING FURTHER EVIDENCE FOR THE ROLE OF IMMUNE FUNCTION. Alzheimer's and Dementia, 2018, 14, P330.	SE 0.8	0
335	ICâ€Pâ€214: HIGH RED MEAT INTAKE IS ASSOCIATED WITH INCREASED TAU ON [¹⁸ F]FLORTAUCIPI PET AND POORER MEMORY. Alzheimer's and Dementia, 2018, 14, P175.	R _{0.8}	0
336	ICâ€Pâ€047: ASSOCIATIONS BETWEEN CORTICAL THICKNESS AND METAMEMORY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P46.	0.8	0
337	F3â€02â€01: ALTERED BILE ACID METABOLITES IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE: RELATION TO NEUROIMAGING AND CSF BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P997.	0.8	0
338	ICâ€Pâ€044: SEPARATION OF FUNCTIONAL CONNECTOMES ACROSS THE AD SPECTRUM BASED ON DISEASEâ€SENSITIVE PRINCIPAL COMPONENTS. Alzheimer's and Dementia, 2018, 14, P43.	0.8	0
339	O3â€13â€04: [18F]â€AVâ€1451 BINDING PROFILE IN EARLY AND LATEâ€ONSET ALZHEIMER'S DISEASE AND SUS NONâ€ALZHEIMER PATHOPHYSIOLOGY. Alzheimer's and Dementia, 2018, 14, P1057.	SPECTED	0
340	P1â€153: DIACYLGLYCEROL PATHWAYâ€RELATED GENE <i>PNPLA2</i> IS ASSOCIATED WITH CSF BIOMARKERS ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P335.	IN 0.8	0
341	P3â€105: GENETIC VARIATION OF ANTIâ€AGING GENE <i>FGF23</i> IS ASSOCIATED WITH LARGER CORTICAL THICKNESS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1107.	0.8	0
342	P1â€320: ASSOCIATIONS BETWEEN CORTICAL THICKNESS AND METAMEMORY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P414.	0.8	0

#	Article	IF	CITATIONS
343	P1â€459: LONGITUDINAL PATTERNS OF DECLINE IN SUBTYPES OF AMNESTIC EARLY ONSET AD. Alzheimer's and Dementia, 2018, 14, P494.	0.8	0
344	ICâ€Pâ€072: GENETIC VARIATION OF ANTIâ€AGING GENE FGF23 IS ASSOCIATED WITH LARGER CORTICAL THICKN IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P64.	VESS 0.8	0
345	Bootstrapped Sparse Canonical Correlation Analysis. , 2018, , 101-117.		0
346	P4â€581: INCREASED DYNAMIC FLEXIBILITY OF FMRIâ€ÐERIVED BRAIN FUNCTIONAL CONNECTIVITY IN PRODROI ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1543.	MAL 0.8	0
347	ICâ€Pâ€093: PLASMA AMYLOIDâ€BETA AND TAU AND VISUAL CONTRAST SENSITIVITY SYNERGISTICALLY PREDIC CEREBRAL AMYLOID AND TAU DEPOSITION ON PET IN PRECLINICAL AND PRODROMAL AD. Alzheimer's and Dementia, 2019, 15, P82.	T 0.8	0
348	ICâ€Pâ€181: EARLY AND LATEâ€ONSET ALZHEIMER'S DISEASE AND SUSPECTED NONâ€ALZHEIMER PATHOPHYS WITHIN THE A/T/N FRAMEWORK. Alzheimer's and Dementia, 2019, 15, P141.	IOLOCY	0
349	ICâ€Pâ€033: COVARYING PATTERNS OF FUNCTIONAL CONNECTIVITY WITH AMYLOID AND TAU DEPOSITION IN EARLY STAGE ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P39.	0.8	0
350	ICâ€Pâ€057: DYSREGULATED FC GAMMA Râ€MEDIATED PHAGOCYTOSIS PATHWAY IN ALZHEIMER'S DISEASE: NETWORKâ€BASED GENE EXPRESSION ANALYSIS. Alzheimer's and Dementia, 2019, 15, P57.	0.8	0
351	ICâ€Pâ€060: GLOBAL CORTICAL [F18]FLORTAUCIPIR ASSOCIATION WITH THE TOP 20 ALZHEIMER'S DISEASE RIS GENES. Alzheimer's and Dementia, 2019, 15, P59.	К _{0.8}	0
352	ICâ€Pâ€066: COGNITIVE IMPAIRMENT IN IN OLDER ADULTS WITH MCI DUE TO SNAP MAY BE PARTIALLY ATTRIBUTABLE TO COMORBID CONDITIONS AND USE OF ANTICHOLINERGIC MEDICATION. Alzheimer's and Dementia, 2019, 15, P63.	0.8	0
353	Relationships of timeâ€varying resting state network stability and cognitive function along the Alzheimer's disease spectrum. Alzheimer's and Dementia, 2020, 16, e040993.	0.8	0
354	Deep learning detection of informative features in [18F] flortaucipir PET for Alzheimer's disease classification. Alzheimer's and Dementia, 2020, 16, e041126.	0.8	0
355	Audioâ€visual speech perception is associated with cerebral tau deposition on [18 F]flortaucipir PET. Alzheimer's and Dementia, 2020, 16, e045297.	0.8	0
356	Dataâ€driven characterization of tau accumulation across the Alzheimer's disease spectrum. Alzheimer's and Dementia, 2020, 16, e045397.	0.8	0
357	Development and validation of composite scores for language and visuospatial functioning in ADNI. Alzheimer's and Dementia, 2020, 16, e045508.	0.8	0
358	Serum metabolome informs neuroimaging biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e045596.	0.8	0
359	Genomeâ€wide analysis of longitudinal Alzheimer's disease biomarker endophenotypes. Alzheimer's and Dementia, 2020, 16, e046295.	0.8	0
360	Influence of rural vs urban county composition on AD neuroimaging biomarkers. Alzheimer's and Dementia, 2020, 16, e046323.	0.8	0

#	Article	IF	CITATIONS
361	Plasma tau is negatively correlated with frontal lobe CBF in hypertensive adults on the AD spectrum. Alzheimer's and Dementia, 2020, 16, e046355.	0.8	0
362	Endophenotype driven polygenic risk scores for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046766.	0.8	0
363	Functional MRI Studies of Memory in Aging, Mild Cognitive Impairment, and Alzheimer's Disease. , 2011, , 419-453.		0
364	Resting State Network Modularity Along the Prodromal Late Onset Alzheimer's Disease Continuum. SSRN Electronic Journal, 0, , .	0.4	0
365	Over-Prescribed Medications/Under-Appreciated Risks. Missouri Medicine, 2016, 113, 275.	0.3	0
366	Polygenic mediation analysis of Alzheimer's disease implicated intermediate amyloid imaging phenotypes. AMIA Annual Symposium proceedings, 2020, 2020, 422-431.	0.2	0
367	Measuring Subjective Cognitive Decline in Older Adults: Harmonization Between the Cognitive Change Index and the Measurement of Everyday Cognition Instruments. Journal of Alzheimer's Disease, 2022, 87, 761-769.	2.6	0
368	Brain activation during episodic scene encoding is associated with amyloid and tau levels in amyloidâ€positive older adults. Alzheimer's and Dementia, 2021, 17, .	0.8	0
369	Longitudinal latent class mixture model analysis identifies subclasses of cognitive/neurodegeneration trajectory with differential patterns of genetic association Alzheimer's and Dementia, 2021, 17 Suppl 3, e056640.	0.8	0